Is this email not displaying correctly? View it in your browser.

06/17/2022 Edition 64 ----- Division of Research -----

Addictions

NIH Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01 Clinical Trial Optional) PAR-19-318 Award Amount: Up to $3,000,000 per year for direct costs. The maximum period of support is 3 years. CFDA #: 93.279 Application Deadline: 09/02/2022 The purpose of this Funding Opportunity Announcement (FOA) is to support research that advances compounds towards FDA approval by leveraging NIDA funds with the strengths and resources of outside organizations, such as for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, and small businesses. Applications from single entities that possess considerable resources for medications development will also be considered, provided the entity demonstrates a significant resource commitment to the proposed project. Project aims can range from the development of a new molecular entity to the expansion of an existing medication's clinical indication(s). Each project should have a defined entry and exit point in the medications development pathway, with the objective of advancement in the FDA approval process. It is hoped that support for these collaborations will accelerate the rate of medications development for SUDs. Track this NIH Strategic Alliances Opportunity in Pivot

NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional) PAR-20-267 Award Amount: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. CFDA #: 93.279 Application Deadline: 09/26/2022 NIDA Core Center of Excellence Grants (P30) are intended to bring together investigators currently funded by NIH or other Federal or non-Federal sources, to enhance the effectiveness of existing research and also to extend the focus of research to substance use/misuse and addiction. It is expected that a Center will transform knowledge in the sciences it is studying. Incremental work should not be the focus of Center activities; rather, new and creative directions are encouraged. An application should integrate and promote research in existing funded projects, to achieve new and creative directions. It is expected that individual core activities reflect a relationship to the integrating theme of the Center and the Center is expected to provide research opportunities and experiences to new investigators, and share findings, data and their resources, consistent with achieving the goals of the program. Track this NIH Center of Excellence Opportunity in Pivot 

NIH Transformative Research on the Basic Mechanisms of Polysubstance Use in Addiction (R01 - Clinical Trial Not Allowed) RFA-DA-23-015 Award Amount: $350,000 direct costs/year. Maximum project period is 5 years. CFDA #: 93.279 LOI Deadline: 10/14/2022 Application Deadline: 11/14/2022 This Funding Opportunity Announcement (FOA) will support projects proposing mechanistic studies that will transform our understanding of polysubstance use in addiction. These hypothesis-based, exploratory projects may investigate mechanisms of polysubstance use at the behavioral, cognitive, cellular, circuit, genetic, epigenetic, pharmacological and/or computational levels. Track this NIH Polysubstance Use Opportunity in Pivot 

Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1-Clinical Trial Not Allowed) RFA-DA-23-014 Award Amount: $300,000 direct costs/year. Maximum project period is 5 years. CFDA #: 93.279 Application Deadline: 08/11/2022 Avenir means future in French, and this Avenir Award Program looks toward the future by supporting early stage investigators proposing highly innovative research in the area of chemistry and pharmacology of substance use disorders and addiction. The purpose of this award is to support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. Track this NIH Avenir Award Opportunity in Pivot

Pathogenic Mechanisms influencing Blood Brain Barrier Function in HIV and Substance Use Disorders (R01 Clinical Trial Optional) RFA-DA-23-012 Award Amount: NIDA intends to commit $2,000,000 if FY2023 to fund 3 to 5 wards. Application budgets are not limited but need to reflect the actual needs of the proposed project. Maximum project period is 5 years. CFDA #: 93.279 Application Deadline: 08/11/2022 This Funding Opportunity Announcement (FOA) supports research on the effects of HIV and addictive substances, acting independently or synergistically on blood brain barrier (BBB) structure and function and the involvement of these effects in HIV associated neuropathology. Track this NIH Substance Use Disorder Opportunity in Pivot

NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional) PAR-20-249 Award Amount: Direct costs are limited to $500,000 per year. The project period duration may range from 3 to 5 years. CFDA #: 93.279 Application Deadline: 08/02/2022 This funding opportunity announcement (FOA) encourages applications for institutional research career development (K12) programs that propose to support intensive supervised research and career development experiences for clinician scientists (Scholars) leading to research independence in the area of substance use and substance use disorder research. Track this NIH Clinical Scientist Development Program Opportunity in Pivot

Alcohol Treatment and Recovery Research (R34 Clinical Trial Required) PAR-22-159 Award Amount: Direct costs are limited to $450,000 over the R34 project period, with no more than $225,000 in any single year. CFDA #: 93.273 Application Deadline: 07/16/2022 The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This FOA will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery. Track this NIH Alcohol Treatment Opportunity in Pivot

Althea Sheets, Research, Scholarly, and Creative Activities Development Manager, Office of Sponsored Programs, althea.sheets@unlv.edu, 702-895-1880